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Introduction {#sec001}
============

Rheumatoid arthritis (RA) is a systemic autoimmune disease which involves inflammation of the synovium and destruction of joint cartilage and bone \[[@pone.0219400.ref001],[@pone.0219400.ref002]\]. RA is pathologically heterogeneous, with many suspected triggers for development of the disease, including environmental \[[@pone.0219400.ref003]\], epigenetic \[[@pone.0219400.ref004]\], and genetic factors \[[@pone.0219400.ref005]--[@pone.0219400.ref007]\] as well as several types of post-translational modifications of proteins \[[@pone.0219400.ref002]\]. The complexity of the disease is further suggested by the various clinical features of RA, as well as the differences in response to therapies among patients treated with synthetic and/or biological disease modifying anti-rheumatic drugs (DMARDs) \[[@pone.0219400.ref002],[@pone.0219400.ref008],[@pone.0219400.ref009]\].

To date, various omics studies have aimed to better understand the molecular pathophysiology of RA and explore the disease condition in individual patients. In recent years, metabolomics has been acknowledged to be a powerful tool for identifying potential biomarkers in RA patients using different types of samples such as plasma, serum, urine, and synovial fluids \[[@pone.0219400.ref010]--[@pone.0219400.ref014]\]. The advantages of metabolomics may not only be in the discovery of biomarkers but also in the identification of rapid physiological responses according to disease activities, as well as in evaluation of the prognosis and therapeutic response to treatment and understanding the pathophysiology of the disease. However, the correlation of the dynamics of metabolites with the disease activity of RA has not been well investigated.

In this study, we obtained urine and plasma samples from biologics-naive RA patients, and searched for metabolites associated with disease activity using capillary electrophoresis quadrupole time-of-flight mass spectrometry (CE-Q-TOFMS). This method allows almost any polar and charged species to be analyzed, combines high-resolution separations with high detection selectivity and sensitivity, and maintains high reproducibility \[[@pone.0219400.ref015],[@pone.0219400.ref016]\].

Materials and methods {#sec002}
=====================

Study cohorts {#sec003}
-------------

The study protocol was approved by the Ethics Committee, Kyoto University Graduate School and Faculty of Medicine. We collected blood and urine from 50 RA patients diagnosed with RA based on the American College of Rheumatology guidelines at the Rheumatic Disease Center, Kyoto University Hospital. The data of one male patient was omitted because he was receiving hemodialysis. No patient had received treatment with biologics, and RA disease activity was categorized based on the 28-joint disease activity score based on erythrocyte sedimentation rate (DAS28-ESR). Patients with DAS28-ESR≥3.2 and those with DAS28-ESR\<3.2 were defined as active and inactive patients, respectively. Other clinical information was obtained from the medical records. Blood was collected from 10 non-RA volunteers matched for age and gender who served as controls. All RA patients and control subjects were recruited from November 2012 to May 2013, and written informed consent was obtained from all participants on the day of sampling.

Sample preparation {#sec004}
------------------

All blood and urine samples were kept at 4°C immediately after collection and processed within 1 hour. Plasma were prepared from EDTA-anticoagulated blood. All plasma and urine samples were aliquoted and stored at -80°C until further analysis.

Metabolomics analysis {#sec005}
---------------------

Plasma or urine samples (50 μL) were added to 450 μL of methanol (134--14523, FUJIFILM Wako Pure Chemical Corporation \[Wako\], Osaka, Japan) containing internal standards (H3304-1002; Human Metabolome Technologies, Inc. \[HMT\], Tsuruoka, Japan), 200 μL of Milli-Q water and 500 μL of chloroform (033--08631, Wako). The samples were then thoroughly mixed by vortex mixer and centrifuged at 9,100 × g at 4°C for 20 min. Subsequently, 350 μL of the upper aqueous layer was centrifugally filtered through a 5-kDa cutoff filter (provided by HMT) at 9,100 × g overnight at 4°C to remove proteins and macromolecules. The filtrate was evaporated and resuspended in 50 μL of Milli-Q water containing internal standards (H3304-1004, HMT) for CE-Q-TOFMS.

A Capillary Electrophoresis System (Agilent Technologies, Santa Clara, California) with an Agilent 6510 Q-TOF mass spectrometer (Agilent Technologies) was used for CE-Q-TOFMS. The fused silica capillary and analysis reagents were provided by HMT. To analyze cationic metabolites, the sample solution was injected at a pressure of 50 mbar for 10 s, and the applied voltage was set at 27 kV. Capillary and fragmenter voltage in positive ion mode were set at 4000 and 80 V. A flow rate of heated dry N2 gas (heater temperature, 300°C) was maintained at 5 psig and 7 L/min. The spectrometer was scanned from *m/z* 100 to 3000. To analyze anionic metabolites, the sample solution was injected at a pressure of 50 mbar for 25 s, and the applied voltage was 30 kV. Capillary and fragmenter voltage in negative ion mode were set at 3500 and 125 V. A flow rate of heated dry N2 gas (heater temperature, 300°C) was maintained at 5 psig and 7 L/min. The spectrometer was scanned from *m/z* 100 to 3000. Other conditions were as described previously \[[@pone.0219400.ref017]\], with slight modifications.

Data processing of MS was started by extracting peaks using MasterHands automatic integration software (Keio University, Tsuruoka, Japan) to obtain peak information, including *m/z*, migration time (MT), and peak area \[[@pone.0219400.ref018]\]. Signal peaks corresponding to isotopomers, adduct ions, and other product ions of known metabolites were excluded, and remaining peaks were annotated with putative metabolites from the MasterHands database based on their MTs and *m/z* values. The tolerance range for the peak annotation was configured at ±0.2 min (Anion)/±1.0min (Cation) for MT and ±40 ppm for *m/z*. In addition, peak areas were normalized against those of the internal standards, and relative area values of urine samples were further normalized by creatinine ^13^C peak. The metabolite IDs were adopted from the Kyoto Encyclopedia of Genes and Genomes database (KEGG, <https://www.genome.jp/kegg/>).

Statistical analysis {#sec006}
--------------------

Student's t test or Welch's t test was performed to assess statistical significance of differences between the two groups using Genedata Analyst (Genedata AG., Basel, Switzerland). Fisher's exact test was performed to assess categorical variables with JMP Pro 12.2.0 (SAS Institute Inc., Cary, NC, USA). Correlation of metabolites with DAS28-ESR was analyzed by the Spearman rank correlation test with JMP Pro. Principal component analysis (PCA), partial least-squares discriminant analysis (PLS-DA) and validation of the PLS-DA model by permutation tests were conducted with normalize metabolomics data using MetaboAnalyst 4.0 (ref \[[@pone.0219400.ref019]\], <http://www.metaboanalyst.ca/>). A multiple logistic regression (MLR) model to discriminate active and inactive cohorts was developed by a stepwise variable selection method (forward and backward selection), conducted with a threshold of p\<0.1 for adding and eliminating features with JMP Pro.

Results {#sec007}
=======

Subject characteristics {#sec008}
-----------------------

The primary characteristics of the RA patients and control subjects are shown in [Table 1](#pone.0219400.t001){ref-type="table"}. We recruited 32 active (DAS28-ESR≥3.2) and 17 inactive (DAS28-ESR\<3.2) RA patients. Most RA patients had been treated with methotrexates and/or glucocorticoids, and none had been treated with biologics.

10.1371/journal.pone.0219400.t001

###### Profiles of control subjects and RA patients.

![](pone.0219400.t001){#pone.0219400.t001g}

                  Control    All RA         P-value[^2)^](#t001fn003){ref-type="table-fn"}   Active RA[^1)^](#t001fn002){ref-type="table-fn"}   Inactive RA[^1)^](#t001fn002){ref-type="table-fn"}   P-value[^3)^](#t001fn004){ref-type="table-fn"}
  --------------- ---------- -------------- ------------------------------------------------ -------------------------------------------------- ---------------------------------------------------- ------------------------------------------------
  Number          10         49                                                              32                                                 17                                                   
  Age             63 ± 14    60 ± 13        0.540                                            61 ± 13                                            59 ± 12                                              0.492
  (range)         (51--86)   (34--81)                                                        (34--81)                                           (34--81)                                             
  Sex ratio       10/0       43/6           0.577                                            27/5                                               16/1                                                 0.650
  (female/male)                                                                                                                                                                                      
  DAS28-ESR       \-         3.71 ± 1.23                                                     4.38 ± 0.94                                        2.46 ± 0.54                                          \<0.001
  (range)                    (1.12--7.62)                                                    (3.23--7.62)                                       (1.12--3.11)                                         
  Treatment       \-         MTX: 39                                                         MTX: 27                                            MTX: 12                                              0.285
                             GCs: 22                                                         GCs: 17                                            GCs: 5                                               0.140

RA, rheumatoid arthritis; DAS28-ESR, disease activity score using 28 joint counts based on erythrocyte sedimentation rate; MTX, methotrexate; GCs, glucocorticoids.

^1)^ Active patients and inactive patients was defined as patients with DAS28-ESR≥3.2 and those with DAS28-ESR\<3.2, respectively.

^2)^ Student's t test or Fisher's exact test between control and RA groups.

^3)^ Student's t test or Fisher's exact test between active and inactive RA groups.

Values are expressed as mean ± standard deviation (SD) and ranges (minimum to maximum).

Comparison of metabolites in plasma between RA patients and control subjects {#sec009}
----------------------------------------------------------------------------

Using the CE-Q-TOFMS method, 104 metabolites in plasma and 217 metabolites in urine were identified and quantified ([S1 Dataset](#pone.0219400.s001){ref-type="supplementary-material"}). Since ketoprofen found in urine was an exogenous metabolite, we excluded it from the following analysis.

First, to evaluate the validity of the collected patient samples, principal component analysis (PCA) was performed using plasma metabolites from RA patients and control subjects, but the results showed no solid separation between the two groups ([S1 Fig](#pone.0219400.s002){ref-type="supplementary-material"}). However, when PLS-DA was performed, results demonstrated an acceptable cluster between the two groups ([Fig 1](#pone.0219400.g001){ref-type="fig"}) with good model parameters (R^2^ = 0.75529, Q^2^ = 0.4068). Validation of the PLS-DA model by permutation tests showed p = 0.022 ([S2 Fig](#pone.0219400.s003){ref-type="supplementary-material"}), which indicated that the separation was significant.

![PLS-DA score plot between RA patients (n = 49) and control subjects (n = 10) based on metabolic profiles in plasma.\
The green and red dots represent RA patient and control samples, respectively.](pone.0219400.g001){#pone.0219400.g001}

When the metabolites from RA patients and controls were compared, we found 24 metabolites that were significantly different (Welch t-test with p\<0.05) between the two groups ([Table 2](#pone.0219400.t002){ref-type="table"}). Some of the metabolites were in agreement with previously published data that compared RA patients and control subjects, such as decreased levels of histidine, methionine, and serine, and increased levels of glyceric acid, phenylalanine, and tyrosine in RA patients \[[@pone.0219400.ref012],[@pone.0219400.ref014],[@pone.0219400.ref020]--[@pone.0219400.ref022]\]. Moreover, the identified metabolites were major intermediates of metabolic pathways, including glycolysis, the tricarboxylic acid (TCA) cycle, and pathways involving amino acid metabolism, which were also in agreement with previous reports \[[@pone.0219400.ref012],[@pone.0219400.ref014]\]. These data suggest that the collected samples were not derived from exceptional RA patients.

10.1371/journal.pone.0219400.t002

###### Metabolites in plasma that were significantly different between RA patients and control subjects.

![](pone.0219400.t002){#pone.0219400.t002g}

  Metabolite                                        KEGG ID          Mode   *m/z*     MT       P-value[^1)^](#t002fn002){ref-type="table-fn"}   Fold change[^2)^](#t002fn003){ref-type="table-fn"}
  ------------------------------------------------- ---------------- ------ --------- -------- ------------------------------------------------ ----------------------------------------------------
  Azelaic acid                                      C08261           A      187.097   12.583   \<0.001                                          -2.98
  N-Acetylleucine                                   C02710           A      172.098   8.229    \<0.001                                          -2.21
  Pyruvic acid                                      C00022           A      87.009    13.462   \<0.001                                          1.99
  Phenylalanine                                     C00079           C      166.087   12.137   \<0.001                                          1.36
  Glycerol-3-phosphate                              C00093           A      171.006   12.623   0.001                                            1.89
  Cysteine-glutathione disulphide                   N/A              C      427.096   12.759   0.002                                            -1.69
  Glutamic acid; threo-beta-methylaspartic acid     C00025; N/A      C      148.061   11.953   0.002                                            1.44
  Glyceric acid                                     C00258           A      105.019   10.814   0.002                                            1.26
  Tyrosine                                          C00082           C      182.082   12.438   0.005                                            1.19
  Cysteine-glutathione disulphide--Divalent         N/A              C      214.052   12.757   0.005                                            -1.56
  Glucuronic acid; Galacturonic acid                C00191; C08348   A      193.035   8.302    0.006                                            1.99
  3-Methylhistidine                                 C01152           C      170.093   8.046    0.007                                            1.70
  Gluconic acid                                     C00257           A      195.051   8.344    0.017                                            1.25
  Threonic acid                                     C01620           A      135.030   9.518    0.020                                            1.32
  Pelargonic acid                                   C01601           A      157.123   8.331    0.023                                            1.14
  gamma-Butyrobetaine                               C01181           C      146.118   8.714    0.024                                            -1.34
  Asymmetric dimethylarginine                       C03626           C      203.149   8.251    0.026                                            1.11
  Serine                                            C00065           C      106.050   10.844   0.028                                            -1.19
  Histidine                                         C00135           C      156.077   7.824    0.029                                            -1.11
  N,N-Dimethylglycine                               C01026           C      104.071   11.945   0.032                                            1.25
  1-Methylnicotinamide                              C02918           C      137.069   7.882    0.037                                            -1.57
  Mucic acid; Glucaric acid                         C00879; C00818   A      209.030   14.658   0.039                                            1.77
  Lactic acid                                       C00186           A      89.025    11.226   0.043                                            1.23
  2-Hydroxybutyric acid; 2-Hydroxyisobutyric acid   C05984; N/A      A      103.040   10.084   0.049                                            1.22

A, anion mode; C, cation mode; MT, migration time; N/A, not applicable

^1)^ P-values are calculated by Welch's t test between RA patients and control subjects.

^2)^ Fold changes are shown as ratio of mean value of RA patients versus that of control subjects. If the number was less than one, the negative value is shown.

Metabolites associated with DAS28-ESR {#sec010}
-------------------------------------

Next, we sought biomarkers that were associated with RA disease activity. We performed PCA between active (DAS28-ESR≥3.2) and inactive (DAS28-ESR\<3.2) patients based on metabolic profiles in plasma and urine, but no solid separation was seen ([S3 Fig](#pone.0219400.s004){ref-type="supplementary-material"}). PLS-DA apparently showed a clear separation, but the result suggested overfitting ([S4 Fig](#pone.0219400.s005){ref-type="supplementary-material"}). Thus, we decided to search for metabolites that significantly correlated with DAS28-ESR. As a result, we found 7 and 8 metabolites that positively and negatively correlated with DAS28-ESR, respectively, in patient plasma samples ([Table 3](#pone.0219400.t003){ref-type="table"}), and 16 and 4 in urine, respectively. There were no overlapping metabolites in both plasma and urine.

10.1371/journal.pone.0219400.t003

###### Metabolites in plasma and urine of RA patients which significantly correlated with DAS28--ESR.

![](pone.0219400.t003){#pone.0219400.t003g}

  Metabolite                                                 KEGG ID          Mode   *m/z*     MT       Spearman ρ   P-value
  ---------------------------------------------------------- ---------------- ------ --------- -------- ------------ ---------
  [***Plasma***]{.ul}                                                                                                
  Glucuronic acid; Galacturonic acid                         C00191; C08348   A      193.035   8.302    0.378        0.007
  Urea                                                       C00086           C      61.041    24.252   0.376        0.008
  N,N-Dimethylglycine                                        C01026           C      104.071   11.945   0.365        0.010
  Gluconic acid                                              C00257           A      195.051   8.344    0.354        0.013
  Cysteine                                                   C00097           C      122.027   12.045   0.298        0.038
  Sarcosine                                                  C00213           C      90.055    10.268   0.292        0.042
  3-Methylhistidine                                          C01152           C      170.093   8.046    0.287        0.046
  4-Methyl-2-oxopentanoic acid; 3-Methyl-2-oxovaleric acid   C00233; C03465   A      129.055   9.865    -0.298       0.038
  Cysteine-glutathione disulphide                            N/A              C      427.096   12.759   -0.306       0.033
  Homoarginine; N6,N6,N6-Trimethyllysine                     C01924; C03793   C      189.141   7.718    -0.318       0.026
  Cysteine-glutathione disulphide -Divalent                  N/A              C      214.052   12.757   -0.323       0.023
  Citric acid                                                C00158           A      191.020   27.938   -0.324       0.023
  Methionine                                                 C00073           C      150.059   11.709   -0.361       0.011
  Guanidoacetic acid                                         C00581           C      118.062   8.874    -0.400       0.005
  Histidine                                                  C00135           C      156.077   7.824    -0.477       0.001
  [***Urine***]{.ul}                                                                                                 
  2-Quinolinecarboxylic acid                                 C06325           A      172.044   9.215    0.378        0.008
  4-Hydroxy-3-methoxymandelic acid; Syringic acid            C05584; C10833   A      197.047   8.349    0.360        0.011
  N-Acetylneuraminic acid                                    C00270           A      308.099   7.282    0.350        0.014
  p-Hydroxyphenylacetic acid; p-Anisic acid                  C00642; C02519   A      151.040   8.898    0.340        0.017
  Homoserine                                                 C00263           C      120.064   10.947   0.325        0.023
  Riboflavin                                                 C00255           C      377.135   25.500   0.322        0.026
  2\'-Deoxycytidine                                          C00881           C      228.090   10.184   0.319        0.026
  Gibberellic acid                                           C01699           A      345.153   7.101    0.318        0.026
  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine               C04599           C      174.124   9.769    0.311        0.030
  gamma-Glu-2-aminobutanoic acid                             N/A              C      233.113   13.643   0.307        0.032
  Methylguanidine                                            C02294           C      74.071    6.578    0.306        0.033
  3-Hydroxy-3-methylglutaric acid                            C03761           A      161.045   16.032   0.302        0.035
  Hypotaurine                                                C00519           C      110.027   20.735   0.298        0.038
  N-Acetylglucosamine 1-phosphate                            C04256           A      300.041   9.910    0.285        0.047
  4-Oxovaleric acid                                          N/A              A      115.040   9.912    0.284        0.048
  Threonic acid                                              C01620           A      135.030   9.479    0.284        0.048
  N6,N6,N6-Trimethyllysine                                   C03793           C      189.160   7.636    -0.283       0.049
  Hypoxanthine                                               C00262           C      137.046   12.041   -0.304       0.034
  gamma-Butyrobetaine                                        C01181           C      146.118   8.695    -0.304       0.034
  Alanine                                                    C00041           C      90.056    9.758    -0.310       0.030

A, anion mode; C, cation mode; MT, migration time; N/A, not applicable

Further, we compared metabolites between active and inactive patients. As shown in [Table 4](#pone.0219400.t004){ref-type="table"}, 9 metabolites in plasma and 15 metabolites in urine were identified to be significantly different (Welch t-test with p\<0.05) between active and inactive RA patients. Again, there were no metabolites that were detected both in plasma and urine.

10.1371/journal.pone.0219400.t004

###### Metabolites in plasma and urine that were significantly different between active RA patients and inactive RA patients.

![](pone.0219400.t004){#pone.0219400.t004g}

  Metabolite                                     KEGG ID          Mode   *m/z*     MT       P-value[^1)^](#t004fn002){ref-type="table-fn"}   Fold change[^2)^](#t004fn003){ref-type="table-fn"}
  ---------------------------------------------- ---------------- ------ --------- -------- ------------------------------------------------ ----------------------------------------------------
  [***Plasma***]{.ul}                                                                                                                        
  Histidine                                      C00135           C      156.077   7.824    0.003                                            -1.13
  Urea                                           C00086           C      61.041    24.252   0.004                                            1.26
  N,N-Dimethylglycine                            C01026           C      104.071   11.945   0.007                                            1.33
  Guanidoacetic acid                             C00581           C      118.062   8.874    0.010                                            -1.30
  Homoarginine; N6,N6,N6-Trimethyllysine         C01924; C03793   C      189.141   7.718    0.011                                            -1.24
  3-Phenylpropionic acid                         C05629           A      149.059   8.998    0.022                                            1.44
  Phenylalanine                                  C00079           C      166.087   12.137   0.024                                            1.27
  3-Indoxylsulfuric acid                         N/A              A      212.002   9.883    0.031                                            1.77
  beta-Alanine                                   C00099           C      90.055    7.868    0.049                                            1.27
  [***Urine***]{.ul}                                                                                                                         
  2-Quinolinecarboxylic acid                     C06325           A      172.044   9.215    0.002                                            3.85
  Gibberellic acid                               C01699           A      345.153   7.101    0.002                                            3.52
  Riboflavin                                     C00255           C      377.135   25.500   0.006                                            9.95
  N-Acetylglucosamine 1-phosphate                C04256           A      300.041   9.910    0.009                                            3.10
  3-Indoxylsulfuric acid                         N/A              A      212.003   9.821    0.013                                            1.74
  m-Hydroxybenzoic acid                          C00587           A      137.023   9.555    0.013                                            2.50
  5-Methoxyindoleacetic acid                     C05660           C      206.077   25.628   0.017                                            2.76
  Hypotaurine                                    C00519           C      110.027   20.735   0.017                                            1.59
  Anserine; Homocarnosine                        C01262; C00884   C      241.130   7.354    0.023                                            2.60
  4-Guanidinobutyric acid                        C01035           C      146.094   8.892    0.023                                            1.48
  Ophthalmic acid                                N/A              C      290.135   14.578   0.024                                            1.48
  Azetidine 2-carboxylic acid                    C08267           C      102.055   9.568    0.030                                            1.72
  2,6-Diaminoheptanedioic acid                   C00666           C      191.102   9.574    0.036                                            3.09
  Betonicine                                     C08269           C      160.097   14.514   0.038                                            4.12
  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine   C04599           C      174.124   9.769    0.039                                            2.08

A, anion mode; C, cation mode; MT, migration time; N/A, not applicable

^1)^ P-values are calculated by Welch's t test between active and inactive RA patients.

^2)^ Fold changes are shown as ratio of mean value of active RA patients versus that of inactive RA patients. If the number was less than one, the negative value is shown.

Consequently, we selected 11 metabolites as biomarker candidates, which significantly correlated with DAS28-ESR, either positively or negatively, as well as those that were significantly different between active and inactive patients. The 11 metabolites were as follows: guanidoacetic acid, histidine, homoarginine or N6,N6,N6-trimethyllysine, N,N-dimethylglycine, and urea in plasma, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 2-quinolinecarboxylic acid, gibberellic acid, hypotaurine, N-acetylglucosamine 1-phosphate, and riboflavin in urine.

MLR analysis {#sec011}
------------

We developed MLR model to search for potential biomarkers of RA disease activity. First, we selected three metabolites, histidine and guanidoacetic acid in plasma and hypotaurine in urine, as MLR variables, which were metabolites that both correlated significantly with DAS28-ESR and significantly differed between active and inactive patients, by stepwise feature selection. Taking these three factors, the model yielded a high value of area under the receiver operating characteristic (ROC) curve (AUC = 0.8934), as shown in [Fig 2](#pone.0219400.g002){ref-type="fig"}. This result indicated that combining plasma and urine metabolomics analysis also identified biomarkers that correlated closely with the disease activity of RA patients.

![ROC curve of the metabolites that correlated with DAS28-ESR and significantly differed between active and inactive patients.\
The selected metabolites in this model were histidine and guanidoacetic acid in plasma and hypotaurine in urine.](pone.0219400.g002){#pone.0219400.g002}

Discussion {#sec012}
==========

In this study, we found several candidate biomarkers of RA disease activity from metabolites in plasma and urine by the CE-Q-TOFMS method. Interestingly, only a few common metabolites were found in plasma and urine, which implied that different biomarkers could be found from the two biofluids. Indeed, we identified two metabolites in plasma, histidine and guanidoacetic acid, and one metabolite, hypotaurine, in urine, as possible biomarkers that may be closely associated with RA disease activity.

As in our study, low histidine concentration has been previously reported in RA \[[@pone.0219400.ref020]--[@pone.0219400.ref022]\], as well as in other diseases, such as chronic kidney disease and gallbladder inflammation with chronic cholecystitis \[[@pone.0219400.ref023], [@pone.0219400.ref024]\]. Since histidine is considered to be an anti-inflammatory and antioxidant factor \[[@pone.0219400.ref025], [@pone.0219400.ref026]\], it may be associated with the inflammation state. However, we found no other metabolites in histidine-related metabolic pathways that are associated with RA disease activity. Thus, further investigation is needed to find the underlying mechanism of how histidine level decreases in RA patients.

Guanidoacetic acid is involved in the arginine metabolism pathway. It is synthesized by the enzyme arginine:glycine amidinotransferase (AGAT) from arginine or glycine. Homoarginine is also synthesized by AGAT from arginine or lysine \[[@pone.0219400.ref027]\], and both guanidoacetic acid and homoarginine were inversely correlated with DAS28-ESR and decreased in active RA patients (Tables [3](#pone.0219400.t003){ref-type="table"} and [4](#pone.0219400.t004){ref-type="table"}). In the pathway, guanidoacetic acid is then synthesized into creatine by guanidoacetic acid N-methyltransferase, which is subsequently catalyzed by creatinase to produce urea and sarcosine, both of which correlated significantly with DAS28-ESR in plasma ([Table 3](#pone.0219400.t003){ref-type="table"}). These data suggest that the metabolism of arginine/glycine/lysine-guanidoacetic acid/homoarginine-urea/sarcosine pathway may be dysregulated as RA disease activity increases. Although only a few reports have reported a decrease in guanidoacetic acid level in disease, low homoarginine concentration is reported to be associated with myocardial dysfunction \[[@pone.0219400.ref028], [@pone.0219400.ref029]\] and renal failure \[[@pone.0219400.ref029], [@pone.0219400.ref030]\], and also affects the production of vasodilator nitric oxide (NO) and mineral metabolism \[[@pone.0219400.ref029]\]. As it is well-known that RA is sometimes comorbid with cardiovascular or renal diseases, dysregulation of the arginine metabolism pathway, represented by lower homoarginine and guanidoacetic acid in active patients, may be closely associated with the risk of these comorbidities.

Hypotaurine, another potential biomarker identified in urine, is reported to be involved in protection against oxidative stress \[[@pone.0219400.ref031]\]. Interestingly, we found in this study that several metabolites in the cysteine and methionine metabolism pathway, which is upstream of the taurine and hypotaurine metabolism pathway, is associated with RA disease activity. For example, cysteine and methionine in plasma positively and inversely correlated with DAS28-ESR, respectively ([Table 3](#pone.0219400.t003){ref-type="table"}). Also, in urine, homoserine and gamma-glutamyl-2-aminobutyrate positively correlated with DAS28-ESR ([Table 3](#pone.0219400.t003){ref-type="table"}), and ophthalmic acid was elevated in active RA patients ([Table 4](#pone.0219400.t004){ref-type="table"}). These are also involved in the cysteine and methionine metabolism pathway. Furthermore, cysteine is known to be a component of the antioxidant glutathione and is involved in the transsulfuration pathway, which consists of interconversion of cysteine and homocysteine through the intermediate cystathionine \[[@pone.0219400.ref032]\]. Since some of the intermediates in this pathway correlate with DAS28-ESR, our study strongly suggests that the reverse transsulfuration pathway is actively induced as RA disease activity increases. Hydrogen sulfide (H~2~S), which is also produced from cysteine, is known as a signaling molecule that regulates the physiological process in inflammations \[[@pone.0219400.ref033], [@pone.0219400.ref034]\], and is reported to be increased in synovial fluids in RA patients \[[@pone.0219400.ref035]\]. Therefore, some pathways downstream of cysteine might be activated and the increase in urinary hypotaurine may represent these metabolic changes in active RA disease.

Taken together, we were able to discover the metabolites from plasma and urine that could be a combinatorial biomarker for RA. This finding supports the use of metabolomics analysis as a promising way to search for disease biomarkers, and to obtain deep insights into the disease pathophysiology, especially with multiple fluid/tissue samples. Metabolomics in combination with other omics methods, such as transcriptomics and proteomics, and the combination of the information obtained with that of other diseases would be beneficial for the better understanding of the state and course of individual RA patients such as with regard to the risk of comorbidity. However, confirming the validity of the biomarker candidates and the significance of the metabolic pathway in RA pathophysiology found in this study requires further study with a new and different set of samples and a larger sample size. We should also confirm whether or not the candidates were specific for RA, because we could not exclude the possibility that the metabolites correlated with the general inflammation process.

Conclusions {#sec013}
===========

We employed metabolic profiling using the CE-Q-TOFMS method to identify metabolites that were associated with disease activity in plasma and urine of patients with rheumatoid arthritis. As a result, we generated a list of metabolites that correlated significantly with DAS28-ESR, as well as metabolites that significantly differed between patients with active and inactive RA. Using both lists, three metabolites---histidine and guanidoacetic acid in plasma and hypotaurine in urine---were selected as MLR variables. Thus, this study demonstrates that the combination of metabolomics analysis of both plasma and urine samples is a useful approach to predicting biomarkers for RA and obtaining deep insights into the pathophysiology of this disease.

Supporting information {#sec014}
======================

###### Metabolomics data with clinical data of RA patients and control subjects.

(XLSX)

###### 

Click here for additional data file.

###### PCA score plot of control subjects and RA patients based on plasma metabolic profile.

The green and red dots represent RA patient and control samples, respectively.

(TIF)

###### 

Click here for additional data file.

###### PLS-DA model validation by permutation tests (n = 1000) based on the plasma metabolic profile of RA patients and control samples.

The p value was p = 0.022 (22/1000).

(TIF)

###### 

Click here for additional data file.

###### PCA score plot of active RA patients (n = 32) and inactive RA patients (n = 17) based on metabolic profiles in plasma and urine.

The red and green dots represent samples of active patients (DAS28-ESR≥3.2) and inactive patients (DAS28-ESR\<3.2), respectively.

(TIF)

###### 

Click here for additional data file.

###### PLS-DA score plot of active RA patients (n = 32) and inactive RA patients (n = 17) based on metabolic profiles in plasma and urine.

The red and green dots represent samples of active patients (DAS28-ESR≥3.2) and inactive patients (DAS28-ESR\<3.2), respectively. R^2^ = 0.95405 and Q^2^ = 0.12656 indicate that the model was overfitted.

(TIF)

###### 

Click here for additional data file.
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